Cargando…
HSP47: A Therapeutic Target in Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collag...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525413/ https://www.ncbi.nlm.nih.gov/pubmed/37760828 http://dx.doi.org/10.3390/biomedicines11092387 |
_version_ | 1785110778133610496 |
---|---|
author | Sakamoto, Noriho Okuno, Daisuke Tokito, Takatomo Yura, Hirokazu Kido, Takashi Ishimoto, Hiroshi Tanaka, Yoshimasa Mukae, Hiroshi |
author_facet | Sakamoto, Noriho Okuno, Daisuke Tokito, Takatomo Yura, Hirokazu Kido, Takashi Ishimoto, Hiroshi Tanaka, Yoshimasa Mukae, Hiroshi |
author_sort | Sakamoto, Noriho |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collagen is the major ECM component and predominant collagen protein deposited in chronic fibrosis, suggesting that type I collagen could be a target of drugs for fibrosis treatment. Heat shock protein 47 (HSP47), encoded by the serpin peptidase inhibitor clade H, member 1 gene, is a stress-inducible collagen-binding protein. It is an endoplasmic reticulum-resident molecular chaperone essential for the correct folding of procollagen. HSP47 expression is increased in cellular and animal models of pulmonary fibrosis and correlates with pathological manifestations in human interstitial lung diseases. Various factors affect HSP47 expression directly or indirectly in pulmonary fibrosis models. Overall, understanding the relationship between HSP47 expression and pulmonary fibrosis may contribute to the development of novel therapeutic strategies. |
format | Online Article Text |
id | pubmed-10525413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105254132023-09-28 HSP47: A Therapeutic Target in Pulmonary Fibrosis Sakamoto, Noriho Okuno, Daisuke Tokito, Takatomo Yura, Hirokazu Kido, Takashi Ishimoto, Hiroshi Tanaka, Yoshimasa Mukae, Hiroshi Biomedicines Review Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collagen is the major ECM component and predominant collagen protein deposited in chronic fibrosis, suggesting that type I collagen could be a target of drugs for fibrosis treatment. Heat shock protein 47 (HSP47), encoded by the serpin peptidase inhibitor clade H, member 1 gene, is a stress-inducible collagen-binding protein. It is an endoplasmic reticulum-resident molecular chaperone essential for the correct folding of procollagen. HSP47 expression is increased in cellular and animal models of pulmonary fibrosis and correlates with pathological manifestations in human interstitial lung diseases. Various factors affect HSP47 expression directly or indirectly in pulmonary fibrosis models. Overall, understanding the relationship between HSP47 expression and pulmonary fibrosis may contribute to the development of novel therapeutic strategies. MDPI 2023-08-25 /pmc/articles/PMC10525413/ /pubmed/37760828 http://dx.doi.org/10.3390/biomedicines11092387 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sakamoto, Noriho Okuno, Daisuke Tokito, Takatomo Yura, Hirokazu Kido, Takashi Ishimoto, Hiroshi Tanaka, Yoshimasa Mukae, Hiroshi HSP47: A Therapeutic Target in Pulmonary Fibrosis |
title | HSP47: A Therapeutic Target in Pulmonary Fibrosis |
title_full | HSP47: A Therapeutic Target in Pulmonary Fibrosis |
title_fullStr | HSP47: A Therapeutic Target in Pulmonary Fibrosis |
title_full_unstemmed | HSP47: A Therapeutic Target in Pulmonary Fibrosis |
title_short | HSP47: A Therapeutic Target in Pulmonary Fibrosis |
title_sort | hsp47: a therapeutic target in pulmonary fibrosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525413/ https://www.ncbi.nlm.nih.gov/pubmed/37760828 http://dx.doi.org/10.3390/biomedicines11092387 |
work_keys_str_mv | AT sakamotonoriho hsp47atherapeutictargetinpulmonaryfibrosis AT okunodaisuke hsp47atherapeutictargetinpulmonaryfibrosis AT tokitotakatomo hsp47atherapeutictargetinpulmonaryfibrosis AT yurahirokazu hsp47atherapeutictargetinpulmonaryfibrosis AT kidotakashi hsp47atherapeutictargetinpulmonaryfibrosis AT ishimotohiroshi hsp47atherapeutictargetinpulmonaryfibrosis AT tanakayoshimasa hsp47atherapeutictargetinpulmonaryfibrosis AT mukaehiroshi hsp47atherapeutictargetinpulmonaryfibrosis |